LitigationUSA
Biotech Patent Litigation Evolves Amid Rising Biosimilar Competition and Cross-Border Disputes
The year 2025 witnessed significant developments in biotech patent litigation, particularly involving biosimilars of aflibercept, a key biologic marketed as Eylea®. Litigation activity intensified across multiple jurisdictions, including England, Germany, the United States, South Korea, and Japan, reflecting a more co…
Wednesday, May 13, 2026